Article
Immunology
Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin, Matthew Hohenboken
Summary: This study evaluated the immunogenicity and safety of an A/H5N1 vaccine using mammalian cell-based technology in different age groups. Results showed that the vaccine met CBER licensure criteria in all age groups, with the highest responses observed in children under 3 years old.
Article
Immunology
Airi Poder, Janine Oberije, Jay Meyer, Peter Heymer, Deborah Molrine, Eve Versage, Leah Isakov, Qiuhong Zhang, Matthew Hohenboken
Summary: Adults aged 50-64 years have a high incidence of symptomatic influenza. This study compared the immunogenicity and safety of an adjuvanted quadrivalent inactivated influenza vaccine with a nonadjuvanted standard dose vaccine in this population. The adjuvanted vaccine showed better immune response, especially in individuals with medical comorbidities.
Letter
Medicine, General & Internal
Odile Launay, Marine Cachanado, Liem B. Luong Nguyen, Laetitia Ninove, Marie Lachatre, Ines Ben Ghezala, Marc Bardou, Catherine Schmidt-Mutter, Karine Lacombe, Fabrice Laine, Jean-Sebastien Allain, Elisabeth Botelho-Nevers, Marie-Pierre Tavolacci, Christian Chidiac, Patricia Pavese, Bertrand Dussol, Stephane Priet, Dominique Deplanque, Amel Touati, Laureen Curci, Eleine Konate, Nadine Ben Hamouda, Anissa Besbes, Eunice Nubret, Florence Capelle, Laurence Berard, Alexandra Rousseau, Eric Tartour, Tabassome Simon, Xavier de Lamballerie
Summary: In a small trial, boost immunization with beta-adjuvanted spike proteins resulted in the highest levels of antibodies and activated T cells after two weeks.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Constantina Boikos, Mahrukh Imran, Van Hung Nguyen, Thierry Ducruet, Gregg C. Sylvester, James A. Mansi
Summary: MF59(R)-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent inactivated influenza vaccine (HD-IIV3) demonstrate enhanced immune response in older adults compared to standard, quadrivalent inactivated influenza vaccines (IIV4). The study shows that aIIV3 is more effective than IIV4 in preventing influenza-related medical encounters in both the 2017-2018 and 2018-2019 seasons, with HD-IIV3 showing comparable effectiveness.
Article
Immunology
Mina C. Hosseinipour, Craig Innes, Sarita Naidoo, Philipp Mann, Julia Hutter, Gita Ramjee, Modulakgotla Sebe, Lucas Maganga, Michael E. Herce, Allan C. DeCamp, Kyle Marshall, One Dintwe, Erica Andersen-Nissen, Georgia D. Tomaras, Nonhlanhla Mkhize, Lynn Morris, Ryan Jensen, Maurine D. Miner, Giuseppe Pantaleo, Song Ding, Olivier Van der Meeren, Susan W. Barnett, M. Juliana McElrath, Lawrence Corey, James G. Kublin
Summary: The study compared different HIV vaccine administration regimens, with the DNA and protein coadministration regimen showing better results in increasing HIV-1 V1/V2 antibody response rate, and DNA administration by Biojector leading to higher CD4(+) T-cell response rates to HIV envelope protein. Both regimens were found to be safe and promising for advancement into efficacy trials.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Patricia Winokur, Hana M. El Sahly, Mark J. Mulligan, Sharon E. Frey, Richard Rupp, Evan J. Anderson, Kathryn M. Edwards, David Bernstein, Kenneth Schmader, Lisa A. Jackson, Wilbur H. Chen, Heather Hill, Abigail Bellamy
Summary: Administration of MF59-adjuvanted H7N9 IIV vaccine in older adults resulted in only modest immune responses, with no significant differences observed between different antigen doses or dosing schedules. The vaccine was generally well tolerated, with a few mild potentially immune mediated adverse events reported.
Article
Immunology
Mark Loeb, Margaret L. Russell, Caralyn Kelly-Stradiotto, Nola Fuller, Kevin Fonseca, David J. D. Earn, Khami Chokani, Lorne Babiuk, Binod Neupane, Pardeep Singh, Eleanor Pullenayegum
Summary: The study found that vaccinating children with MF59 adjuvanted trivalent influenza vaccine did not significantly reduce influenza infection rates in children and family members compared to inactivated quadrivalent vaccine, but it did result in significant protection against influenza A in children.
Article
Immunology
Michele A. Kohli, Michael Maschio, Shannon Cartier, Joaquin Mould-Quevedo, Frank-Ulrich Fricke
Summary: This research compares the cost-effectiveness of different influenza vaccines for individuals aged 65 years and above in Germany. The results indicate that the enhanced quadrivalent influenza vaccine (aQIV) has similar clinical effectiveness to the high dose antigen vaccine (QIV-HD), but is cost-saving compared to QIV-HD at current unit prices.
Review
Microbiology
Maria Pilar Arrazola Martinez, Jose Maria Eiros Bouza, Pere Plans Rubio, Joan Puig-Barbera, Jesus Ruiz Aragon, Alvaro Torres Lana
Summary: MF59-adjuvanted vaccines have been shown to be effective in boosting the immune response in individuals aged 65 or over, reducing the risk of hospital admission and providing cross-protection against different strains of influenza. They are also safe for use in all age groups.
REVISTA ESPANOLA DE QUIMIOTERAPIA
(2023)
Article
Immunology
Pornthep Chanthavanich, Eve Versage, Esther Van Twuijver, Matthew Hohenboken
Summary: The study showed that administering the MF59-adjuvanted, cell culture-derived A/H5N1 influenza vaccine to children aged 6 months through 17 years resulted in significantly increased immunogenicity against heterologous strains, with the highest responses observed against the A/H5N1 Egypt/2010 strain.
Review
Virology
Eamon O. Murchu, Laura Comber, Karen Jordan, Sarah Hawkshaw, Liam Marshall, Michelle O'Neill, Mairin Ryan, Conor Teljeur, Annasara Carnahan, Jaime Jesus Perez, Anna Hayman Robertson, Kari Johansen, Jorgen de Jonge, Tyra Krause, Nathalie Nicolay, Hanna Nohynek, Ioanna Pavlopoulou, Richard Pebody, Pasi Penttinen, Marta Soler-Soneira, Ole Wichmann, Patricia Harrington
Summary: This systematic review investigated the efficacy, effectiveness, and safety of MF59(R) adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza. The study found that MF59(R) adjuvanted trivalent vaccines were effective in preventing influenza in older adults, but there was no significant difference between adjuvanted and non-adjuvanted vaccines. However, the adjuvanted vaccines were associated with more local adverse events and systemic reactions compared to traditional vaccines.
REVIEWS IN MEDICAL VIROLOGY
(2023)
Article
Immunology
Giuseppe Palladino, Annette Ferrari, Nedzad Music, Ethan C. Settembre, Yingxia Wen
Summary: Vaccination is the most effective method to reduce morbidity and mortality caused by influenza infection, with vaccines highly sensitive to antigenic changes. Adjuvants can increase cross-reactive immunity, and studies have shown that adjuvanted vaccines are more effective in younger subjects during seasons with antigenic differences between circulating and vaccine viruses.
Article
Public, Environmental & Occupational Health
Marta Lopez-Fauqued, Maribel Co-van der Mee, Adriana Bastidas, Pierre Beukelaers, Alemnew F. Dagnew, Juan Jose Fernandez Garcia, Anne Schuind, Fernanda Tavares-da-Silva
Summary: Recombinant zoster vaccine has been shown to have a clinically acceptable safety profile in immunocompromised populations at an increased risk of herpes zoster. The safety data, along with previously published efficacy and immunogenicity results, support a favorable benefit-risk profile for the vaccination in this high-risk group.
Article
Biotechnology & Applied Microbiology
Sharon S. S. Frey, Eve Versage, Esther Van Twuijver, Matthew Hohenboken
Summary: A study found that the MF59-adjuvanted H5N1 influenza vaccine can provide cross-protection against different strains of the virus and generate a strong immune response in different age groups.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Jorge Jacob, Tor Biering-Sorensen, Lars Holger Ehlers, Christina H. Edwards, Kristin Greve-Isdahl Mohn, Anna Nilsson, Jonas Hjelmgren, Wenkang Ma, Yuvraj Sharma, Emanuele Ciglia, Joaquin Mould-Quevedo
Summary: This study evaluated the cost-effectiveness of the MF59 (R)-adjuvanted quadrivalent influenza vaccine (aQIV) compared to the traditional standard-dose quadrivalent influenza vaccine (SD-QIV) and the high-dose quadrivalent influenza vaccine (HD-QIV) for adults aged 65 years and above in Denmark, Norway, and Sweden. The results showed that vaccination with aQIV could prevent a significant number of influenza infections, hospitalizations, and deaths compared to SD-QIV. From a healthcare payer perspective, aQIV was cost-effective in all three countries and was cost saving compared to HD-QIV.
Article
Pharmacology & Pharmacy
Domenico Italiano, Annalisa Capuano, Angela Alibrandi, Rosarita Ferrara, Angelo Cannata, Gianluca Trifiro, Janet Sultana, Carmen Ferrajolo, Michele Tari, Daniele Ugo Tari, Margherita Perrotta, Claudia Pagliaro, Concita Rafaniello, Edoardo Spina, Vincenzo Arcoraci
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2015)
Article
Pharmacology & Pharmacy
Barbara Rinaldi, Maria Donniacuo, Loredana Sodano, Giulia Gritti, Eugenio Martuscelli, Augusto Orlandi, Concetta Rafaniello, Francesco Rossi, Luigino Calzetta, Annalisa Capuano, Maria Gabriella Matera
BRITISH JOURNAL OF PHARMACOLOGY
(2015)
Editorial Material
Oncology
Morena Fasano, Carminia Maria Della Corte, Annalisa Capuano, Ferdinando Carlo Sasso, Federica Papaccio, Liberato Berrino, Fortunato Ciardiello, Floriana Morgillo
CLINICAL LUNG CANCER
(2015)
Article
Clinical Neurology
Samuele Cortese, Pietro Panei, Romano Arcieri, Elena A. P. Germinario, Annalisa Capuano, Lucia Margari, Flavia Chiarotti, Paolo Curatolo
Article
Endocrinology & Metabolism
Concetta Rafaniello, Vincenzo Arcoraci, Carmen Ferrajolo, Liberata Sportiello, Maria Giuseppa Sullo, Francesco Giorgianni, Gianluca Trifiro, Michele Tari, Achille P. Caputi, Francesco Rossi, Katherine Esposito, Dario Giugliano, Annalisa Capuano
DIABETES RESEARCH AND CLINICAL PRACTICE
(2015)
Article
Pharmacology & Pharmacy
Marco Pozzi, Dario Cattaneo, Sara Baldelli, Serena Fucile, Annalisa Capuano, Carmela Bravaccio, Liberata Sportiello, Silvana Bertella, Fabiana Auricchio, Renato Bernardini, Carmen Ferrajolo, Giuseppe Guastella, Elisa Mani, Carla Carnovale, Simone Pisano, Concetta Rafaniello, Maria Pia Riccio, Renata Rizzo, Maria Grazia Scuderi, Serena Sperandeo, Laura Villa, Antonio Pascotto, Massimo Molteni, Francesco Rossi, Sonia Radice, Emilio Clementi
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2016)
Review
Cardiac & Cardiovascular Systems
Annalisa Capuano, Cristina Scavone, Cristiana Vitale, Liberata Sportiello, Francesco Rossi, Giuseppe M. C. Rosano, Andrew J. Stewart Coats
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2015)
Article
Pharmacology & Pharmacy
Monia Donati, Anita Conforti, Maria Carmela Lenti, Annalisa Capuano, Oscar Bortolami, Domenico Motola, Ugo Moretti, Alfredo Vannacci, Concetta Rafaniello, Alberto Vaccheri, Elena Arzenton, Roberto Bonaiuti, Liberata Sportiello, Roberto Leone
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2016)
Review
Public, Environmental & Occupational Health
Annamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, Maurizio Sessa, Daniela Cimmaruta, Francesco Rossi, Annalisa Capuano
Review
Cardiac & Cardiovascular Systems
Liberata Sportiello, Concetta Rafaniello, Cristina Scavone, Cristiana Vitale, Francesco Rossi, Annalisa Capuano
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2016)
Article
Pharmacology & Pharmacy
Concetta Rafaniello, Carmen Ferrajolo, Maria Giuseppa Sullo, Maurizio Sessa, Liberata Sportiello, Antonio Balzano, Francesco Manguso, Maria Luisa Aiezza, Francesco Rossi, Carmelo Scarpignato, Annalisa Capuano
PHARMACOLOGICAL RESEARCH
(2016)
Review
Cardiac & Cardiovascular Systems
Vincenzo Mollace, Micaela Gliozzi, Annalisa Capuano, Francesco Rossi
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2017)
Article
Respiratory System
Maria Gabriella Matera, Annalisa Capuano, Mario Cazzola
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2015)
Review
Pediatrics
Simone Pisano, Gennaro Catone, Stefania Veltri, Valentina Lanzara, Marco Pozzi, Emilio Clementi, Raffaella Iuliano, Maria Pia Riccio, Sonia Radice, Massimo Molteni, Annalisa Capuano, Antonella Gritti, Giangennaro Coppola, Annarita Milone, Carmela Bravaccio, Gabriele Masi
ITALIAN JOURNAL OF PEDIATRICS
(2016)
Article
Pharmacology & Pharmacy
Annalisa Capuano, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello, Pierluigi Fusco, Macella De Vizia, Fausto Ferraro
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS
(2015)